 SAN DIEGO, Aug. 11, 2021 GLOBE NEWSWIRE -- Sorrento Therapeutics, Inc. NASDAQ: SRNE; Sorrento, a clinical stage biopharmaceutical company developing new therapies to treat cancer, pain and COVID-19, and Dyadic International, Inc. NASDAQ: DYAI; Dyadic, a global biotechnology company focused on further improving, applying and deploying its proprietary C1-cell protein production platform to accelerate development, lower production costs and improve access to biologic vaccines and drugs at flexible commercial scales, today announced the signing of a binding term sheet to enter into an exclusive license agreement to develop and commercialize vaccines, therapeutics, and diagnostics for coronaviruses, including Dyadics lead COVID-19 vaccine candidate, DYAI-100, produced using Dyadics proprietary and patented C1-cell protein production platform. The final terms of the license will be set forth in a definitive agreement to be entered into between the parties. 